Resistin becomes less futile

University of Pennsylvania researchers have removed a roadblock to studying the role of resistin in diabetes by developing a mouse model that has human-like expression of the target. Although the model may become a tool to study how the adipokine participates in the development of type 2 diabetes, it isn't clear if it will rekindle enthusiasm for resistin itself as a drug target.

When resistin was discovered in 2001, it seemed like a slam-dunk diabetes target-the adipokine was produced in rodent fat cells, ...